RWD(Real-World Data) 시장 : 컴포넌트별, 데이터 소스별, 배포 모델별, 용도별, 치료 영역별, 최종사용자별 - 시장 규모, 업계 동향, 기회 분석 및 예측(2026-2035년)

The global real-world data (RWD) market is undergoing rapid expansion as pharmaceutical companies, healthcare providers, biotechnology firms, research organizations, and other healthcare stakeholders increasingly recognize the value of evidence generated from routine clinical practice. The market was valued at approximately USD 1.92 billion in 2025 and is projected to reach USD 7.31 billion by 2035, representing a compound annual growth rate (CAGR) of 14.30% during the 2026-2035 forecast period.

One of the most significant factors contributing to market expansion is the global shift toward precision medicine. Conventional treatment strategies often rely on broad patient populations, whereas precision medicine seeks to identify therapies and interventions that are better suited to the biological, genetic, clinical, and demographic characteristics of individual patients. Real-world data can provide researchers with extensive information about patient characteristics, treatment histories, disease progression, treatment responses, and clinical outcomes.

Noteworthy Market Developments

The global real-world data (RWD) market is characterized by strong competition among major healthcare information, analytics, technology, and clinical research companies. IQVIA, Flatiron Health, Optum, Syneos Health, and Oracle Cerner have established prominent positions.

IQVIA maintains a particularly strong position in the RWD market through its extensive global healthcare information ecosystem and advanced analytics capabilities. Flatiron Health has established a specialized position within the RWD market through its strong focus on oncology.

Optum has developed another major competitive advantage through its extensive healthcare and payer ecosystem. Syneos Health differentiates itself by combining real-world evidence capabilities with extensive experience in clinical research and contract research services. Oracle Cerner brings a different competitive advantage through its extensive presence within hospital and healthcare information infrastructure.

Core Growth Driver

Rising clinical trial costs and high failure rates are major factors driving the growth of the real-world data (RWD) market. Pharmaceutical and biotechnology companies face substantial financial and operational challenges when developing new therapies, with significant investments required across discovery, preclinical research, clinical development, regulatory submissions, and commercialization. The risk of failure remains considerable, particularly during clinical-stage development, where unsuccessful trials can result in the loss of years of research and hundreds of millions of dollars in development expenditure. As a result, life science companies are increasingly turning to real-world data to improve decision-making, reduce avoidable development risks, and increase the efficiency of clinical research programs.

Emerging Opportunity Trends

AI- and NLP-powered data curation is emerging as a significant opportunity for growth in the real-world data (RWD) market. Healthcare organizations, pharmaceutical companies, biotechnology firms, and research institutions generate enormous volumes of information in both structured and unstructured formats. While structured data such as laboratory values, medication codes, diagnoses, and procedure records can be readily incorporated into databases, a substantial amount of clinically valuable information remains embedded within unstructured physician notes, pathology reports, discharge summaries, radiology reports, and other narrative documentation. Advanced artificial intelligence and natural language processing (NLP) technologies are increasingly being deployed to convert this complex narrative information into standardized and analysis-ready datasets.

Barriers to Optimization

Data privacy and regulatory liabilities represent a significant challenge that may restrain the growth of the global real-world data (RWD) market. The increasing use of electronic health records, claims databases, patient registries, genomic information, and other healthcare datasets has created substantial opportunities for research and analytics, but it has also increased the complexity of protecting sensitive patient information. Healthcare data can contain highly confidential clinical, demographic, genetic, and treatment-related information, making organizations particularly vulnerable to privacy breaches, unauthorized access, inappropriate data sharing, and regulatory violations. As the volume of healthcare information used for research and commercial purposes continues to expand, maintaining strong privacy and governance controls is becoming increasingly critical.

Detailed Market Segmentation

By component, data assets and databases occupy a leading position in the global real-world data (RWD) market, supported by the rapidly increasing demand for high-quality, longitudinal, and AI-ready healthcare datasets. Pharmaceutical companies, biotechnology firms, healthcare providers, research organizations, and technology companies increasingly recognize that the value of advanced analytics and artificial intelligence depends heavily on the quality, completeness, accessibility, and structure of the underlying data. As organizations seek to develop more sophisticated clinical, commercial, and research applications, demand for comprehensive databases capable of supporting longitudinal patient analysis has increased substantially.

By data source, electronic health records (EHRs) represent the leading source within the global real-world data (RWD) market. Their dominant position is supported by the depth, breadth, and clinical detail of information captured throughout routine patient care. Unlike data sources that primarily focus on financial or administrative transactions, EHR systems can contain longitudinal information covering diagnoses, clinical observations, laboratory results, medications, procedures, treatment histories, and other patient-level variables. This comprehensive view enables researchers and pharmaceutical companies to follow patient trajectories over time and generate detailed insights into how diseases progress and how treatments perform under real-world conditions.

By application, drug development and clinical research represent the leading segment of the global real-world data (RWD) market, accounting for approximately 55% of the overall market share. Its dominant position reflects the growing use of real-world data to supplement conventional clinical trial evidence, improve research efficiency, identify suitable patient populations, and support evidence generation throughout the pharmaceutical development lifecycle. Pharmaceutical companies and research organizations are increasingly incorporating information from electronic health records, claims databases, patient registries, disease-specific databases, and other healthcare sources into clinical development strategies. The expanding availability of large-scale healthcare datasets has consequently positioned RWD as an important component of modern drug research.

By end user, pharmaceutical companies represent the leading segment of the global real-world data (RWD) market, accounting for approximately 34% of the market share. Their dominant position is primarily driven by the growing need to use evidence generated from routine clinical practice to support drug development, regulatory submissions, market access, safety monitoring, and commercial decision-making. Pharmaceutical companies increasingly rely on real-world data from electronic health records, insurance claims, patient registries, clinical databases, pharmacy records, and other healthcare sources to complement evidence generated through traditional clinical trials. The increasing availability of large and diverse healthcare datasets has therefore made RWD an important strategic resource throughout the pharmaceutical product lifecycle.

Segment Breakdown

By Component

• Data Assets & Databases
• Analytics & Technology Platforms
• Services
• Data Aggregation Services
• Data Curation & Integration Services
• RWE Generation Services
• Consulting Services
• Regulatory & Market Access Support

By Data Source

• Electronic Health Records (EHRs)
• Claims & Billing Data
• Patient Registries
• Pharmacy Data
• Genomics & Omics Data
• Wearable & Remote Monitoring Data
• Patient-Generated Health Data
• Laboratory Data
• Imaging Data

By Deployment Model

• Cloud-Based
• On-Premise
• Hybrid

By Application

• Drug Development & Clinical Research
• Pharmacovigilance & Drug Safety
• Regulatory Decision Support
• Market Access & Reimbursement
• Precision Medicine
• Clinical Outcome Assessment
• Healthcare Operations & Population Health Management
• Health Economics & Outcomes Research (HEOR)

By Therapeutic Area

• Oncology
• Cardiology
• Neurology
• Immunology
• Rare Diseases
• Metabolic Disorders
• Infectious Diseases
• Respiratory Diseases
• Others

By End User

• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations (CROs)
• Healthcare Providers
• Payers & Insurance Organizations
• Government & Regulatory Agencies
• Academic & Research Institutes

By Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa (MEA)
• Saudi Arabia
• South Africa
• UAE
• Rest of MEA
• South America
• Argentina
• Brazil
• Rest of South America

Geography Breakdown

• North America led the global market in 2025, accounting for approximately 44% of the total market share. The region's strong position was supported by its advanced healthcare infrastructure, high levels of digital technology adoption, significant investments in health information systems, and growing emphasis on interoperability across healthcare organizations.
• The United States has played a central role in accelerating healthcare technology integration through the widespread adoption of electronic health records and standardized digital health information systems. Major hospitals and healthcare networks have invested heavily in interoperable platforms designed to allow patient information to be exchanged across different providers, facilities, laboratories, pharmacies, and other healthcare stakeholders.
• Canada has also made an important contribution to North America's market position through the continued expansion of digital health infrastructure across its provincial healthcare systems. Canadian healthcare organizations have increasingly adopted electronic medical records, digital health platforms, and centralized or interconnected registries to improve access to patient information and support more coordinated care.

Leading Market Participants

• IQVIA Holding Inc.
• IBM Corporation
• Tempus Labs Inc.
• Syneos Health Inc.
• Evidera Inc.
• Palantir Technologies Inc.
• SAS Institute
• Flatiron Health
• Optum Inc.
• Cerner Corporation
• Other Prominent Players

Table of Content

Chapter 1. Executive Summary

• 1.1. Global Real-World Data (RWD) Market

Chapter 2. Research Methodology & Research Framework

• 2.1. Research Objective
• 2.2. Product Overview
• 2.3. Market Segmentation
• 2.4. Qualitative Research
  • 2.4.1. Primary Sources
  • 2.4.2. Secondary Sources
• 2.5. Quantitative Research
  • 2.5.1. Primary Sources
  • 2.5.2. Secondary Sources
• 2.6. Breakdown of Primary Research Respondents, By Region
• 2.7. Assumption for Study
• 2.8. Market Size Estimation
• 2.9. Data Triangulation

Chapter 3. Global Real-World Data (RWD) Market Overview

• 3.1. Industry Value Chain Analysis
  • 3.1.1. Data-Source (EHR, Claims, Registry, Pharmacy, Wearable) Originators
  • 3.1.2. Data Aggregation, Curation, Tokenization & De-Identification Providers
  • 3.1.3. Analytics & Technology Platform (RWE Generation) Developers
  • 3.1.4. Consulting, Regulatory & Market-Access Support Partners
  • 3.1.5. End Users (Pharma, Biotech, CROs, Providers, Payers, Government, Academia)
• 3.2. Industry Outlook
  • 3.2.1. Overview of the Global Real-World Data (RWD) & Real-World Evidence (RWE) Industry
  • 3.2.2. RWD/RWE Supplementing RCTs for Regulatory Decisions, External Control Arms & Label Expansion
  • 3.2.3. EHR Interoperability, Tokenization, AI-Ready Genomic-Clinical Linked Datasets & Privacy-Governed Monetization
• 3.3. PESTLE Analysis
• 3.4. Porter's Five Forces Analysis
  • 3.4.1. Bargaining Power of Suppliers
  • 3.4.2. Bargaining Power of Buyers
  • 3.4.3. Threat of New Entrants
  • 3.4.4. Threat of Substitutes
  • 3.4.5. Intensity of Rivalry
• 3.5. Market Growth and Outlook
  • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
  • 3.5.2. Price Trend Analysis, By Component

Chapter 4. Global Real-World Data (RWD) Market Analysis

• 4.1. Competition Dashboard
  • 4.1.1. Market Concentration Rate
  • 4.1.2. Company Market Share Analysis (Value %), 2025
  • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Real-World Data (RWD) Market Analysis

• 5.1. Market Dynamics and Trends
  • 5.1.1. Growth Drivers
  • 5.1.2. Restraints
  • 5.1.3. Opportunity
  • 5.1.4. Key Trends
• 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 5.2.1. By Component
    • 5.2.1.1. Key Insights
      • 5.2.1.1.1. Data Assets & Databases
      • 5.2.1.1.2. Analytics & Technology Platforms
      • 5.2.1.1.3. Services
      • 5.2.1.1.4. Data Aggregation Services
      • 5.2.1.1.5. Data Curation & Integration Services
      • 5.2.1.1.6. RWE Generation Services
      • 5.2.1.1.7. Consulting Services
      • 5.2.1.1.8. Regulatory & Market Access Support
  • 5.2.2. By Data Source
    • 5.2.2.1. Key Insights
      • 5.2.2.1.1. Electronic Health Records (EHRs)
      • 5.2.2.1.2. Claims & Billing Data
      • 5.2.2.1.3. Patient Registries
      • 5.2.2.1.4. Pharmacy Data
      • 5.2.2.1.5. Genomics & Omics Data
      • 5.2.2.1.6. Wearable & Remote Monitoring Data
      • 5.2.2.1.7. Patient-Generated Health Data
      • 5.2.2.1.8. Laboratory Data
      • 5.2.2.1.9. Imaging Data
  • 5.2.3. By Deployment Model
    • 5.2.3.1. Key Insights
      • 5.2.3.1.1. Cloud-Based
      • 5.2.3.1.2. On-Premise
      • 5.2.3.1.3. Hybrid
  • 5.2.4. By Application
    • 5.2.4.1. Key Insights
      • 5.2.4.1.1. Drug Development & Clinical Research
      • 5.2.4.1.2. Pharmacovigilance & Drug Safety
      • 5.2.4.1.3. Regulatory Decision Support
      • 5.2.4.1.4. Market Access & Reimbursement
      • 5.2.4.1.5. Precision Medicine
      • 5.2.4.1.6. Clinical Outcome Assessment
      • 5.2.4.1.7. Healthcare Operations & Population Health Management
      • 5.2.4.1.8. Health Economics & Outcomes Research (HEOR)
  • 5.2.5. By Therapeutic Area
    • 5.2.5.1. Key Insights
      • 5.2.5.1.1. Oncology
      • 5.2.5.1.2. Cardiology
      • 5.2.5.1.3. Neurology
      • 5.2.5.1.4. Immunology
      • 5.2.5.1.5. Rare Diseases
      • 5.2.5.1.6. Metabolic Disorders
      • 5.2.5.1.7. Infectious Diseases
      • 5.2.5.1.8. Respiratory Diseases
      • 5.2.5.1.9. Others
  • 5.2.6. By End User
    • 5.2.6.1. Key Insights
      • 5.2.6.1.1. Pharmaceutical Companies
      • 5.2.6.1.2. Biotechnology Companies
      • 5.2.6.1.3. Contract Research Organizations (CROs)
      • 5.2.6.1.4. Healthcare Providers
      • 5.2.6.1.5. Payers & Insurance Organizations
      • 5.2.6.1.6. Government & Regulatory Agencies
      • 5.2.6.1.7. Academic & Research Institutes
  • 5.2.7. By Region
    • 5.2.7.1. Key Insights
      • 5.2.7.1.1. North America
        • 5.2.7.1.1.1. The U.S.
        • 5.2.7.1.1.2. Canada
        • 5.2.7.1.1.3. Mexico
      • 5.2.7.1.2. Europe
        • 5.2.7.1.2.1. Western Europe
          • 5.2.7.1.2.1.1. The UK
          • 5.2.7.1.2.1.2. Germany
          • 5.2.7.1.2.1.3. France
          • 5.2.7.1.2.1.4. Italy
          • 5.2.7.1.2.1.5. Spain
          • 5.2.7.1.2.1.6. Rest of Western Europe
        • 5.2.7.1.2.2. Eastern Europe
          • 5.2.7.1.2.2.1. Poland
          • 5.2.7.1.2.2.2. Russia
          • 5.2.7.1.2.2.3. Rest of Eastern Europe
      • 5.2.7.1.3. Asia Pacific
        • 5.2.7.1.3.1. China
        • 5.2.7.1.3.2. India
        • 5.2.7.1.3.3. Japan
        • 5.2.7.1.3.4. Australia & New Zealand
        • 5.2.7.1.3.5. South Korea
        • 5.2.7.1.3.6. ASEAN
        • 5.2.7.1.3.7. Rest of Asia Pacific
      • 5.2.7.1.4. Middle East & Africa (MEA)
        • 5.2.7.1.4.1. Saudi Arabia
        • 5.2.7.1.4.2. South Africa
        • 5.2.7.1.4.3. UAE
        • 5.2.7.1.4.4. Rest of MEA
      • 5.2.7.1.5. South America
        • 5.2.7.1.5.1. Argentina
        • 5.2.7.1.5.2. Brazil
        • 5.2.7.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

• 6.1. Market Dynamics and Trends
  • 6.1.1. Growth Drivers
  • 6.1.2. Restraints
  • 6.1.3. Opportunity
  • 6.1.4. Key Trends
• 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 6.2.1. Key Insights
    • 6.2.1.1. By Component
    • 6.2.1.2. By Data Source
    • 6.2.1.3. By Deployment Model
    • 6.2.1.4. By Application
    • 6.2.1.5. By Therapeutic Area
    • 6.2.1.6. By End User
    • 6.2.1.7. By Country

Chapter 7. Europe Market Analysis

• 7.1. Market Dynamics and Trends
  • 7.1.1. Growth Drivers
  • 7.1.2. Restraints
  • 7.1.3. Opportunity
  • 7.1.4. Key Trends
• 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 7.2.1. Key Insights
    • 7.2.1.1. By Component
    • 7.2.1.2. By Data Source
    • 7.2.1.3. By Deployment Model
    • 7.2.1.4. By Application
    • 7.2.1.5. By Therapeutic Area
    • 7.2.1.6. By End User
    • 7.2.1.7. By Country

Chapter 8. Asia Pacific Market Analysis

• 8.1. Market Dynamics and Trends
  • 8.1.1. Growth Drivers
  • 8.1.2. Restraints
  • 8.1.3. Opportunity
  • 8.1.4. Key Trends
• 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 8.2.1. Key Insights
    • 8.2.1.1. By Component
    • 8.2.1.2. By Data Source
    • 8.2.1.3. By Deployment Model
    • 8.2.1.4. By Application
    • 8.2.1.5. By Therapeutic Area
    • 8.2.1.6. By End User
    • 8.2.1.7. By Country

Chapter 9. Middle East & Africa (MEA) Market Analysis

• 9.1. Market Dynamics and Trends
  • 9.1.1. Growth Drivers
  • 9.1.2. Restraints
  • 9.1.3. Opportunity
  • 9.1.4. Key Trends
• 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 9.2.1. Key Insights
    • 9.2.1.1. By Component
    • 9.2.1.2. By Data Source
    • 9.2.1.3. By Deployment Model
    • 9.2.1.4. By Application
    • 9.2.1.5. By Therapeutic Area
    • 9.2.1.6. By End User
    • 9.2.1.7. By Country

Chapter 10. South America Market Analysis

• 10.1. Market Dynamics and Trends
  • 10.1.1. Growth Drivers
  • 10.1.2. Restraints
  • 10.1.3. Opportunity
  • 10.1.4. Key Trends
• 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 10.2.1. Key Insights
    • 10.2.1.1. By Component
    • 10.2.1.2. By Data Source
    • 10.2.1.3. By Deployment Model
    • 10.2.1.4. By Application
    • 10.2.1.5. By Therapeutic Area
    • 10.2.1.6. By End User
    • 10.2.1.7. By Country

Chapter 11. Company Profile

Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

• 11.1. IQVIA Holding Inc.
• 11.2. IBM Corporation
• 11.3. Tempus Labs Inc.
• 11.4. Syneos Health Inc.
• 11.5. Evidera Inc.
• 11.6. Palantir Technologies Inc.
• 11.7. SAS Institute
• 11.8. Flatiron Health
• 11.9. Optum Inc.
• 11.10. Cerner Corporation
• 11.11. Other Prominent Players

Chapter 12. Annexure

• 12.1. List of Secondary Sources
• 12.2. Key Country Markets- Macro Economic Outlook/Indicators